Skip Navigation HRSA - Health Resources and Service Administration U.S. Department of Health & Human Services
Home
Questions
Order Publications
 
Grants Find Help Service Delivery Data Health System Concerns About HRSA

The HIV/AIDS Program: Draft HAB Performance Measures

 
< Previous | Home | Next >


AIDS Drug Assistance Program: Formulary

  Performance Measure
  Numerator
  Denominator
  Patient Exclusions
  Data Element
  Data Sources
  National Goals, Targets or Benchmarks for Comparison
  Basis for Selection
  US Public Health Service Guidelines
  References/Notes
 
Performance Measure: ADAP: Eligibility Recertification  TOP
Related OPR Measure: No

Percentage of new anti-retroviral classes that are included in the ADAP formulary within 90 days of the date of inclusion of new anti-retroviral classes in the PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents [ 1 ] during the measurement year.

 
Numerator  TOP

Number of new anti-retroviral classes included into the ADAP formulary within 90 days of the publication of updated PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents that include new anti-retroviral drug class during the measurement year.

 
Denominator  TOP

Total number of new antiretroviral classes published in updated PHS Guidelines during the measurement year.

 
Exclusions  TOP
  1. PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents published in the last ninety days of the measurement year.
 
Data Element  TOP
  1. Did the updated PHS Guidelines for the Use of Antiretroviral Agents in HIV-1- infected Adults and Adolescents include any new anti-retroviral classes? (Y/N)
    1. If yes, (for each new class) was the new class included into the ADAP formulary within 90 days of publication of updated PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents? (Y/N)
      1. If yes, list the date of publication of PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents and date of inclusion in the ADAP formulary.
 
Data Sources  TOP
  • ADAP quarterly report
  • ADAP formulary
 
National Goals, Targets, or Benchmarks for Comparison  TOP

100% (Measure is a statutory requirement.)

 
Basis for Selection  TOP

The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415) [ 2 ] mandates that the state-operated ADAP programs “shall ensure that the therapeutics included on the list of classes of core antiretroviral therapeutics established by the Secretary under subsection (e) are, at a minimum, the treatments provided by the State pursuant to this section”. HRSA/HAB has notified Part B grantees of that all ADAPs must include agents from each of the core antiretroviral classes listed in PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents.[ 3 ] These legislative and policy requirements have been specified in the Part B ADAP Grant Application.[ 4 ]

 
US Public Health Service Guidelines  TOP

US Public Health Service Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents [ 1 ] contains the list of classes of core antiretroviral therapeutics to be included in ADAP formularies.

 
References/Notes  TOP

[1] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Download in printer-friendly format (pdf 1.7MB)

[2] The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415), Section 202(a).

[3] HRSA/HAB, Policy Notice-07-03, "The Use of Ryan White HIV/AIDS Program, Part B (formerly Title II), AIDS Drug Assistance Program (ADAP) Funds for Access, Adherence and Monitoring Services", September 2007.

[4] Program Guidance: HIV Care Grant Program Part B: States/Territories Formula and Supplemental Awards and AIDS Drug Assistance Program Formula and Supplemental Awards, HRSA Announcement Numbers: HRSA 08-091.